Barbui, C, Esposito, E, Cipriani, A (2009). Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 180, 291–297.
Bjorkenstam, C, Moller, J, Ringback, G, Salmi, P, Hallqvist, J, Ljung, R (2013). An association between initiation of selective serotonin reuptake inhibitors and suicide – a nationwide register-based case-crossover study. PLoS ONE 8, e73973.
Courtet, P, Lopez-Castroman, J, Jaussent, I, Gorwood, PA (2014). Antidepressant dosage and suicidal ideation. JAMA Internal Medicine 174, 1863–1865.
Gibbons, RD, Brown, CH, Hur, K, Marcus, SM, Bhaumik, DK, Erkens, JA, Herings, RM, Mann, JJ (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356–1363.
Hammad, TA, Laughren, T, Racoosin, J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 63, 332–339.
Hetrick, SE, Mckenzie, JE, Cox, GR, Simmons, MB, Merry, SN (2012). Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 11, CD004851.
Hill, AB (1965). The environment and disease: association or causation? Proceedings of the Royal Society of Medicine 58, 295–300.
Miller, M, Swanson, SA, Azrael, D, Pate, V, Sturmer, T (2014). Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Internal Medicine 174, 899–909.
Sharma, T, Guski, LS, Freund, N, Gotzsche, PC (2016). Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 352, i65.
Stone, MB (2014). The FDA warning on antidepressants and suicidality--why the controversy? New England Journal of Medicine 371, 1668–1671.